Evidence map›Paper›PMID 33960631›Full record

ArticleJournal of cellular and molecular medicine2021

Blue LED causes autophagic cell death in human osteosarcoma by increasing ROS generation and dephosphorylating EGFR.

Mingyu He, Gege Yan, Yang Wang, Rui Gong, Hong Lei, Shuting Yu, Xiaoqi He, Guanghui Li, Weijie Du, Tianshuai Ma and 10 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Mingyu HeDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Gege YanDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Yang WangDepartment of Orthopedics, Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Rui GongDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Hong LeiDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Shuting YuDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Xiaoqi HeDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Guanghui LiDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Weijie DuDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Tianshuai MaDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Manqi GaoDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Meixi YuDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Shenzhen LiuDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Zihang XuDepartment of Pharmacology, College of Pharmacy (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), Harbin Medical University, Harbin, China.
Elina IdiiatullinaCentral Laboratory of Scientific Research, Bashkir State Medical University, Ufa, Russia.
Naufal ZagidullinCentral Laboratory of Scientific Research, Bashkir State Medical University, Ufa, Russia.
Valentin PavlovCentral Laboratory of Scientific Research, Bashkir State Medical University, Ufa, Russia.
Benzhi CaiDepartment of Orthopedics, Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID 0000-0003-0017-867X
Ye YuanDepartment of Orthopedics, Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Lei YangDepartment of Orthopedics, Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Harbin Medical University · CNBashkir State Medical University · RU

Funding

CAMS Innovation Fund for Medical Sciences 2019-I2M-5-078China Postdoctoral Science Foundation 2018M630365Distinguished Youth Foundation of the First Affiliated Hospital of Harbin Medical University HYD2020JQ0013Heilongjiang Innovative Talent Training Fund for Young Teachers 601 UNPYSCT-2017073National Key Research and Development Program of China 2017YFB0403802National Natural Science Fund of China 81603146
6 · The paper itself

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumour in adolescence. Lately, light-emitting diodes (LED)-based therapy has emerged as a new promising approach for several diseases. However, it remains unknown in human OS. Here, we found that the blue LED irradiation significantly suppressed the proliferation, migration and invasion of human OS cells, while we observed blue LED irradiation increased ROS production through increased NADPH oxidase enzymes NOX2 and NOX4, as well as decreased Catalase (CAT) expression levels. Furthermore, we revealed blue LED irradiation-induced autophagy characterized by alterations in autophagy protein markers including Beclin-1, LC3-II/LC3-I and P62. Moreover, we demonstrated an enhanced autophagic flux. The blockage of autophagy displayed a remarkable attenuation of anti-tumour activities of blue LED irradiation. Next, ROS scavenger N-acetyl-L-cysteine (NAC) and NOX inhibitor diphenyleneiodonium (DPI) blocked suppression of OS cell growth, indicating that ROS accumulation might play an essential role in blue LED-induced autophagic OS cell death. Additionally, we observed blue LED irradiation decreased EGFR activation (phosphorylation), which in turn led to Beclin-1 release and subsequent autophagy activation in OS cells. Analysis of EGFR colocalization with Beclin-1 and EGFR-immunoprecipitation (IP) assay further revealed the decreased interaction of EGFR and Beclin-1 upon blue LED irradiation in OS cells. In addition, Beclin-1 down-regulation abolished the effects of blue LED irradiation on OS cells. Collectively, we concluded that blue LED irradiation exhibited anti-tumour effects on OS by triggering ROS and EGFR/Beclin-1-mediated autophagy signalling pathway, representing a potential approach for human OS treatment.

Indexed as

Autophagic Cell DeathApoptosisBone NeoplasmsCell MovementCell ProliferationErbB ReceptorsHumansLightOsteosarcomaPhosphorylationReactive Oxygen SpeciesTumor Cells, CulturedEGFR protein, humanErbB ReceptorsReactive Oxygen Speciesautophagybeclin-1blue light-emitting diodes (LED)cell deathepidermal growth factor receptor (EGFR)mitochondrial reactive oxygen species (ROS)osteosarcoma (OS)

Identifiers

PMID33960631
PMCPMC8178260
OpenAlexW3159831349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.